點(diǎn)擊圖片查看原圖
中文名稱：替格瑞洛雜質(zhì)，替卡格雷雜質(zhì)對照品
英文名稱：Ticagrelor Impurity
規(guī)格：10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途：實(shí)驗(yàn)研發(fā)，藥品申報(bào)檢測，不得用于臨床醫(yī)學(xué)診斷。
隨貨提供：所有雜質(zhì)對照品均隨貨提供HPLC，NMR，MS圖譜及CoA證書。
保存及取用：為了防止產(chǎn)品含量降低，應(yīng)防潮，避光和抗氧化包裝，保存應(yīng)以提高物質(zhì)穩(wěn)定性為原則。如果一次使用很少量，可以將其適當(dāng)分裝后使用，這樣可以有效的防止試劑污染。請不要在臟亂和強(qiáng)光環(huán)境中取用，以免造成污染和失效。
替格瑞洛雜質(zhì)，替卡格雷雜質(zhì)對照品 雜質(zhì)列表：
| Ticagrelor | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 1 | (1R,2R,3S,5R)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 2 | (1S,2S,3R,5S)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 3 | (1R,2R,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 4（Mixture of Diastereomers） | (1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol compound with (1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1:1) |
| Ticagrelor Impurity 5（Mixture of Diastereomers） | (1R,2R,3S,5R)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol compound with (1R,2R,3S,5R)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1:1) |
| Ticagrelor Impurity 6 | 2-(((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy)ethyl acetate |
| Ticagrelor Impurity 7 | (1S,2S,3R,5S)-3-(7-hydroxy-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 8 | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 9 | 2-(((3aR,4S,6R,6aS)-6-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol |
| Ticagrelor Impurity 10 | 5-amino-6-chloro-2-(propylthio)pyrimidin-4-ol |
| Ticagrelor Impurity 11 | 2-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)oxy)ethanol |
| Ticagrelor Impurity 12 | (1S,2S,3R,5S)-3-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 13 | 5-amino-6-(((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)amino)-2-(propylthio)pyrimidin-4-ol |
| Ticagrelor Impurity 14 | (1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 15 | (1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-methoxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 16 | 2-(((3aS,4R,6S,6aR)-6-((3-((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol |
| Ticagrelor Impurity 17 | (1R,2R,3S,5R)-3-((3-((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 18 | (1S,2S,3R,5S)-3-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 19 | (1S,2S,3R,5S)-3-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 20 | (1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol |
| Ticagrelor Impurity 21 | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 22 | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 23 | sodium 7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-3-((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-olate |
| Ticagrelor Impurity 24 | (1S,2S,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 25 | (1S,2S,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 26 | 2-((6-chloro-5-(7-(2-hydroxyethoxy)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2-(propylthio)pyrimidin-4-yl)oxy)ethanol |
| Ticagrelor Impurity 27 | (1S,2S,3S,5R)-3-(7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Ticagrelor Impurity 28 | 7-chloro-3-(4,6-dichloro-2-(propylthio)pyrimidin-5-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine |
| Ticagrelor Impurity 29 | (1S,2S,3R,5S)-3-(2-hydroxyethoxy)-5-(5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2-diol |
| Ticagrelor Impurity 30 | 2-(((3aR,4R,6S,6aS)-6-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol |
替格瑞洛雜質(zhì)，替卡格雷雜質(zhì)對照品 訂購方式：
聯(lián)系人：何先生
手機(jī)：15012456311
QQ：781007885
郵箱：phastandards@gmail.com
歡迎您通過電話，電郵或在線客服向我司詢價(jià)及訂購產(chǎn)品。
替格瑞洛雜質(zhì)，替卡格雷雜質(zhì)對照品 深圳遠(yuǎn)揚(yáng)專注醫(yī)藥標(biāo)準(zhǔn)品，雜質(zhì)對照品，更多產(chǎn)品，歡迎選購（篇幅有限，只列舉了一小部分，更多更全，請來電詳詢）：
NIBSC標(biāo)準(zhǔn)品部分產(chǎn)品列表：
01/534 Meningococcal serogroup W polysaccharide
13/223 C-Peptide, Human. 78st International Standard.
13/154 Influenza Antigen B/Massachusetts/02/2032 (Egg derived)
10/192 Reteplase Reference Material
10/119 Reteplase Reference Material
03/104-064 HTLV-49 (antibody) Monitor Sample
03/104-080 HTLV-65 (antibody) Monitor Sample
10/151 Reteplase Reference Material
12/B623-072 QCRFLUAH1N1QC1-Influenza AH1N1 QC70
12/B623-049 QCRFLUAH1N1QC1-Influenza AH1N1 QC47
13/149 C-Peptide, Human. 4st International Standard.
13/232 Influenza Antigen B/Massachusetts/02/2110 (Egg derived)
10/195 Reteplase Reference Material
10/204 Reteplase Reference Material
12/B623-060 QCRFLUAH1N1QC1-Influenza AH1N1 QC58
03/104-061 HTLV-46 (antibody) Monitor Sample
13/189 Influenza Antigen B/Massachusetts/02/2067 (Egg derived)
07/343 BCG Vaccine of Russian BCG-I sub-strain(70st WHO Reference Reagent)
13/292 Polio Anti Sabin type 75 (inactivated) Serum
10/143 Reteplase Reference Material
10/158 Reteplase Reference Material
13/156 C-Peptide, Human. 11st International Standard.
07/370 BCG Vaccine of Russian BCG-I sub-strain(97st WHO Reference Reagent)
13/141 Influenza Antigen B/Massachusetts/02/2019 (Egg derived)
95/557 Interleukin-18 (Human, rDNA derived)
95/568 Interleukin-29 (Human, rDNA derived)
13/181 Influenza Antigen B/Massachusetts/02/2059 (Egg derived)
95/574 Interleukin-35 (Human, rDNA derived)
13/222 C-Peptide, Human. 77st International Standard.
07/296 BCG Vaccine of Russian BCG-I sub-strain(23st WHO Reference Reagent)
13/275 Polio Anti Sabin type 58 (inactivated) Serum
03/104-109 HTLV-94 (antibody) Monitor Sample
10/164 Reteplase Reference Material
95/625 Interleukin-86 (Human, rDNA derived)
10/134 Reteplase Reference Material
10/110 Reteplase Reference Material
13/323 Polio Anti Sabin type 106 (inactivated) Serum
10/202 Reteplase Reference Material
10/168 Reteplase Reference Material
10/129 Reteplase Reference Material
03/104-123 HTLV-108 (antibody) Monitor Sample
替格瑞洛雜質(zhì)，替卡格雷雜質(zhì)對照品 雜質(zhì)對照品部分產(chǎn)品列表：別嘌醇雜質(zhì)，亞胺培南雜質(zhì)，氫溴酸西酞普蘭雜質(zhì)，比魯卡因雜質(zhì)， ，普里米酮雜質(zhì)，布美他尼雜質(zhì)，伊班膦酸鈉雜質(zhì)，羅沙替丁雜質(zhì)，格列吡嗪雜質(zhì)，沃替西汀雜質(zhì)，鹽酸阿夫唑嗪雜質(zhì)，地拉羅司雜質(zhì)，馬西替坦雜質(zhì)，芐絲肼雜質(zhì)，鹽酸特拉唑嗪雜質(zhì)，艾普拉唑雜質(zhì)，吡羅昔康雜質(zhì)，丁呋洛爾雜質(zhì)，文拉法辛雜質(zhì)，阿替洛爾雜質(zhì)，地西他濱雜質(zhì)，氟喹酮雜質(zhì)，醋氯芬酸雜質(zhì)，凡德他尼雜質(zhì)，卡泊芬凈雜質(zhì)，噻托溴銨雜質(zhì)，昂丹司瓊雜質(zhì)，貝沙羅汀雜質(zhì)，萬古霉素雜質(zhì)，地諾孕素雜質(zhì)，依匹唑派雜質(zhì)，甲磺酸帕珠沙星，阿斯巴甜雜質(zhì)，西那卡塞雜質(zhì)，蘭索拉唑雜質(zhì)，LCZ696雜質(zhì)，Lesinurad雜質(zhì)，瑞他帕林雜質(zhì)，酒石酸美托洛爾雜質(zhì)，法莫替丁雜質(zhì)，博舒替尼雜質(zhì)，環(huán)丙沙星雜質(zhì)，達(dá)托霉素雜質(zhì)，維格列汀雜質(zhì)，厄洛替尼雜質(zhì)，貝那普利雜質(zhì)，泰地唑胺雜質(zhì)，西米替丁雜質(zhì)，克霉唑雜質(zhì)，匹莫范色林雜質(zhì)，多索茶堿雜質(zhì)，喜樹堿雜質(zhì)，丁吡卡因雜質(zhì)，伏立康唑雜質(zhì)，吉非替尼雜質(zhì)，埃博霉素A雜質(zhì)，利伐沙班雜質(zhì)，氰美馬嗪雜質(zhì)